Cytomegalovirus Infection Treatments

Find Cytomegalovirus Infection Treatments

Brand Name

Valcyte

Generic Name
Valganciclovir
View Brand Information
FDA approval date: March 29, 2001
Classification: Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor
Form: Tablet, Powder, For

What is Valcyte (Valganciclovir)?

VALCYTE is a deoxynucleoside analogue cytomegalovirus DNA polymerase inhibitor indicated for: Adult Patients.
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances

Related Clinical Trials

Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)

Background: \- KSHV inflammatory cytokine syndrome (KICS) is a newly recognized disease caused by Kaposi sarcoma-associated herpesvirus (KSHV). This virus can cause cancer. People with KICS can have severe symptoms. They include fever, weight loss, and fluid in the legs or abdomen. People with KICS may also be at risk of getting other cancers associated with KSHV. These cancers include Kaposi sarcoma and lymp...

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs

Summary: The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treati...

Initial Safety Lead-in Followed by a Phase II Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection (The Breast CMV Study)

Summary: This is a phase II trial with an initial safety lead-in evaluating the efficacy, safety, neurocognitive, and quality-of-life outcomes of anti-cytomegalovirus (CMV) therapy and standard-of-care (SOC) in patients with anti-human cytomegalovirus (HCMV)-reactivated brain metastases. Male and female patients, aged ≥18 years, who have metastatic breast cancer with progressive brain metastases and CMV vi...